Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101844 | 0.81 | LMNA (0.48) | LMNAHPGDCYP1A2CYP2C9GRIK1 | |
| SCHEMBL22192129 | 0.81 | LMNA (0.48) | LMNAHPGDCYP1A2CYP2C9GRIK1 | |
| SCHEMBL1507331 | 0.77 | MAOB (0.46) | LMNAHPGDCYP1A2CYP2C9GRIK1 | |
| SCHEMBL4827392 | 0.76 | HDAC1 (0.38) | LMNAHPGDMAOBALDH1A1KDM4E | |
| SCHEMBL28023700 | 0.75 | LMNA (0.43) | LMNAHPGDCYP1A2CYP2C9GRIK1 | |
| SCHEMBL2380962 | 0.75 | KDM4E (0.48) | LMNAMAOBALDH1A1KDM4EPOLB | |
| SCHEMBL28312134 | 0.74 | SMN1; SMN2 (0.41) | LMNAHPGDMAOBALDH1A1KDM4E | |
| SCHEMBL18760121 | 0.73 | LMNA (0.42) | LMNAHPGDCYP1A2CYP2C9GRIK1 | |
| SCHEMBL11708948 | 0.72 | ALDH1A1 (0.49) | LMNAHPGDALDH1A1KDM4EPOLB | |
| SCHEMBL6072978 | 0.72 | ASF1A (0.37) | LMNAHPGDGRIK1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207091-A1 | DRUG DELIVERY IMPLANTS WITH BI-DIRECTIONAL DELIVERY CAPACITY AND METHODS OF USING SAME | GLAUKOS CORP (US) | 2024-06-27 | — | — | US | disclosed |
| US-11992551-B2 | Implants with controlled drug delivery features and methods of using same | GLAUKOS CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| CN-113893085-B | Systems and methods for delivering multiple ocular implants | 格劳科斯公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11925578-B2 | Drug delivery implants with bi-directional delivery capacity | GLAUKOS CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240065887-A1 | DRUG DELIVERY IMPLANTS AS INTRAOCULAR DRUG DEPOTS AND METHODS OF USING SAME | GLAUKOS CORPORATION | 2024-02-29 | — | — | US | disclosed |
| EP-4289416-A2 | DRUG ELUTING OCULAR IMPLANT | Dose Medical Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4282390-A2 | IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES | Dose Medical Corporation (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3785683-B1 | DRUG ELUTING OCULAR IMPLANT | DOSE MEDICAL CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3603590-B1 | IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES | DOSE MEDICAL CORP (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230301830-A1 | DRUG-ELUTING OCULAR IMPLANT | GLAUKOS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2010093945-A2 | UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME | GLAUKOS CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-2136851-A2 | A COATING OF FAST ABSORPTION OR DISSOLUTION | Abbott Cardiovascular Systems, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1732621-B1 | PHOSPHOLIPID AND NON-FOULING COATING COMPOSITIONS | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-2088976-A2 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | Glaukos Corporation (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090134100-A1 | ELONGATED FILM TAPE, METHOD OF USING SAME TO PREPARE A FILTER, FILTER AND METHOD OF USING FILTER | TESA AG | 2009-05-28 | — | — | US | disclosed |
| US-20080228127-A1 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | GLAUKOS CORPORATION (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008076731-A2 | A COATING OF FAST ABSORPTION OR DISSOLUTION | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080145393-A1 | Coating of fast absorption or dissolution | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008061043-A2 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | GLAUKOS CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20050208093-A1 | Phosphoryl choline coating compositions | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145393-A1 | Coating of fast absorption or dissolution | TNNC1, SLC10A2, SI | LMNA 2240/4885HPGD 1362/4885CYP1A2 273/4885 |
| US-20050208093-A1 | Phosphoryl choline coating compositions | PHOSPHO1, CHKA, SGMS1 | LMNA 961/4885HPGD 2830/4885CYP1A2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.